Generic vs Brand Name Drugs: Same Company or Different

Here is a question that breaks most people's mental model of the pharmacy: when your brand-name drug goes generic, does a different company actually make the cheaper version? Often, no. The company selling the generic is frequently the same company that sold the brand, or a spin-off that used to be part of it.

Novartis carved out its entire generics division into Sandoz in October 2023. Pfizer merged its off-patent drugs with Mylan to create Viatris in 2020, and still runs one of America's largest generic injectable businesses through Hospira. Teva, the world's largest generics maker, sells blockbuster branded drugs on the side.

We traced the ownership of the generic drug industry, and the line between "brand" and "generic" is blurrier than the price gap suggests.

The Generic Drug Question

When a drug patent expires, competitors can file Abbreviated New Drug Applications (ANDAs) with the FDA and sell bioequivalent copies, usually at a fraction of the price. Consumers assume the cheap version comes from a scrappy challenger.

The reality is more circular. The innovator company often sells an "authorized generic" itself, spins off its generics arm into a separate company, or quietly holds the ANDA through a subsidiary. The brand and the copy frequently share corporate DNA, and in some cases shared manufacturing lines.

Four companies explain almost the whole map: Teva, Sandoz, Viatris, and Pfizer.

Teva: The World's Largest Generic Drugmaker

Teva Pharmaceutical Industries (NYSE: TEVA) is the biggest generic drug company on earth by both total and new prescriptions, commanding more than 6% of the US generics market. The Israeli company, headquartered in Tel Aviv, fills roughly one in every fifteen prescriptions in America.

But Teva is no longer a pure generics company. Management has spent years shifting capital toward higher-margin innovative drugs and biosimilars. Its branded portfolio now drives the growth story: Austedo for movement disorders, Ajovy for migraine, and Uzedy for schizophrenia. Teva expects its biosimilars business, developed partly through a partnership with Alvotech, to generate about $800 million in revenue by 2027.

The company that built its name on commodity generics is deliberately becoming a diversified biopharma. That pivot tells you everything about where generic margins went.

Sandoz: The Novartis Spin-Off

On October 4, 2023, Novartis completed the largest structural reorganization in modern pharma: it spun off its entire generics and biosimilars division as Sandoz (SIX Swiss Exchange: SDZ), an independent public company.

The split was surgical. About 95% of the generic ANDAs historically held by the combined organization went to Sandoz, leaving Novartis as a pure innovative-medicine company. Payers now evaluate Sandoz as a direct competitor to its former parent's branded products.

Sandoz's first years as a standalone have been steady. First-quarter 2026 net sales reached $2.76 billion, up 3% year over year, and biosimilars now account for nearly a third of total revenue, the highest share in the industry. Growth came from newer launches like Afqlir, its biosimilar to Eylea, and Pyzchiva, its biosimilar to Stelara. Sandoz is to Novartis what a generic is to a brand: the same molecule, different label.

Viatris: The Mylan-Pfizer Merger

Viatris (NASDAQ: VTRS) exists because Pfizer wanted out of old brands. In November 2020, Pfizer combined Upjohn, its off-patent drugs unit holding names like Lipitor and Viagra, with Mylan, the generics maker famous for the EpiPen. The merged company, Viatris, instantly became the second-largest generic manufacturer in the world.

Viatris then spent five years simplifying. It sold its biosimilars business to Biocon Biologics in November 2022 for roughly $3.3 billion. It divested its over-the-counter business to Cooper Consumer Health for $2.17 billion. It sold rights in women's health and active pharmaceutical ingredients. The company that was itself assembled from leftovers has been trimming everything that is not complex generics and branded generics in emerging markets.

The corporate family tree here is worth a second look. Your generic Lipitor is a Viatris product, which means it descends from Pfizer's own off-patent division and Mylan's generics machine at once.

Pfizer: The Brand Giant With a Generic Side

Pfizer (NYSE: PFE) is known as the ultimate brand-name company: Eliquis (co-marketed with Bristol-Myers Squibb), Ibrance, Xtandi, and Xeljanz represent more than $20 billion in annual revenue facing patent expiry between 2026 and 2030, one of the steepest cliffs in industry history.

What is less known: Pfizer is also a major generic manufacturer. Through its Hospira subsidiary, acquired for $17 billion in 2015, Pfizer is the largest supplier of generic sterile injectable medications to US hospitals. The company holds hundreds of approved ANDAs covering hospital staples, and those generic and mature products dominate its operational footprint even as the branded portfolio dominates the income statement.

So when a hospital buys a generic injectable, there is a real chance the "generic company" supplying it is Pfizer, the same firm defending its branded blockbusters from generic entry elsewhere.

The Same Company, Different Name

The pattern repeats across the industry. Novartis kept the innovative drugs and spun the generics to Sandoz. Pfizer parked its off-patent brands in Viatris and kept Hospira's generics inside. Teva sells Austedo at brand prices while filling generic prescriptions at commodity margins.

The authorized generic is the clearest example of the overlap. When a patent expires, the innovator can launch its own generic version, manufactured on the same line, often before independent competitors arrive. Pfizer ran an internal authorized generics unit for years. Novartis used Sandoz the same way before the spin-off. The strategy captures the price-sensitive customer the brand was going to lose anyway.

For the buyer, the distinction matters less than the marketing suggests. An authorized generic is literally the brand product relabeled. A spun-off generics unit often makes its copies in the same facilities its former parent used. When we track these relationships in our database, the "generic vs brand" question frequently resolves to "same corporate family, different invoice."

The Biosimilar Revolution

The industry's next generic wave targets biologics, the complex injectable drugs that now dominate pharma revenue. Generic versions of biologics are called biosimilars, and every major generics player is repositioning around them.

Sandoz leads, with biosimilars near a third of revenue and launches across immunology and ophthalmology. Teva is building through its Alvotech partnership. Viatris exited the space entirely by selling to Biocon. Even the brand giants feel it: biosimilars to Keytruda and Entresto are the most watched patent cliffs of the late 2020s.

The shift means the "generic companies" of the next decade will look more like biotechs, with development pipelines and clinical trials, and less like commodity manufacturers racing to zero margin.

The Ownership Comparison

Sources: company filings, Sandoz Q1 2026 results, Novartis spin-off documentation, Viatris divestiture releases.

What This Means for Brand Ownership

Generic vs brand-name drugs is not a story of independent challengers versus incumbents. It is a story of the same corporate portfolios sorted into different boxes. The generic your pharmacy substitutes may come from a company spun out of the brand's own parent, or from a business unit the brand company still owns outright.

That matters for consumers tracking where their money goes. Buying "the cheaper generic" does not necessarily mean buying from a different company. For the bigger picture, read our complete guide to pharmaceutical brand ownership, Pfizer vs Johnson & Johnson portfolios, and the 15 pharmacy brands and their corporate parents.

Frequently Asked Questions

Are generic drugs made by the same company as brand-name drugs? Often yes, or by a company the brand's parent created. Innovators sell "authorized generics" of their own drugs, and giants like Pfizer manufacture generic injectables through Hospira. Novartis transferred about 95% of its generic applications to Sandoz when it spun the unit off.

Who is the largest generic drug manufacturer? Teva Pharmaceutical Industries (NYSE: TEVA) is the world's largest by total and new prescriptions, with more than 6% of the US market. Sandoz and Viatris round out the top tier.

What was the Sandoz spin-off? On October 4, 2023, Novartis separated its generics and biosimilars division into Sandoz (SIX: SDZ), an independent public company. Sandoz took roughly 95% of the combined generic drug applications and now competes directly with its former parent.

Does Pfizer make generic drugs? Yes. Through Hospira, acquired in 2015, Pfizer is the largest supplier of generic sterile injectables to US hospitals and holds hundreds of approved generic applications alongside its branded portfolio.

The Bottom Line

The generic aisle is not a rebellion against Big Pharma. It is Big Pharma's second checkout lane. Teva, Sandoz, Viatris, and Pfizer between them prove that the companies fighting patent cliffs and the companies profiting from them are often the same ones.

Want to see who makes your medication? Check Teva, Sandoz, or Pfizer in our database.

Explore Related Brands

• Lipitor - Pfizer's cholesterol blockbuster now in the Viatris portfolio
• Viagra - Off-patent Pfizer brand inside Viatris
• Eliquis - Pfizer/BMS anticoagulant facing generic entry in the late 2020s
• Entresto - Novartis heart drug nearing its patent cliff
• Keytruda - Merck's cancer giant and the biggest biosimilar target ahead

Browse all healthcare and pharmaceutical brands →

Sources

1. Novartis. Sandoz spin-off completion announcement. October 4, 2023. novartis.com 2. Sandoz Group AG. Q1 2026 interim results. sandoz.com 3. Viatris Inc. Biosimilars divestiture to Biocon Biologics (November 2022) and OTC divestiture releases. 4. Pfizer Inc. Form 10-K and patent cliff disclosures, 2025-2026. 5. Teva Pharmaceutical. Investor day materials and biosimilars guidance, 2025-2026. 6. Morningstar / MarketLine generics industry analyses, 2026.

All brand ownership data verified through WhoBrands.com's research methodology. Last updated: October 30, 2026.